COVID-19 and Anticoagulants

19 December 2022

Recent evidence shows potentially significant drug interactions may occur between COVID-19 treatments, including Paxlovid, Lagevrio and Veklury and anticoagulants. Broadly speaking:

Lagevrio – there are no reported significant drug interactions with anticoagulants, particularly with Direct Oral Anticoagulants (DOACs) at this time.

Paxlovid – there are important interactions with anticoagulants, particularly with DOACs and also with warfarin.

Veklury – may increase or decrease the anticoagulant effect of warfarin.  Such interactions can impact on laboratory monitoring of anticoagulant use and the safe use of anticoagulants. 

It is advised that drug interactions are checked if patients are commenced on the above-listed COVID-19 treatments. Refer to the product information sheets; additionally, the following links provide information on potentially significant drug interactions: 

It is recommended that you consult with a pharmacist as well as the appropriate clinical services if potentially significant drug interactions are identified.

General News


World Food Safety Day 2023

You may not know it, but SA Pathology has a Food and Environ...


Uncommon Investigations – Barmah Forest Virus

SA Pathology performs over 15m tests a year from a catalogue...


AI and Pathology

How AI is looking to the future SA Pathology’s Associate P...


Diagnosing Coeliac

May is Coeliac Awareness Month Does everyone with a sensit...


Uncommon Investigations – Q fever

SA Pathology performs over 15m tests a year from a catalogue...